Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses an interview with Dr. Tsuji about hair follicle stem cell multiplication and the financial challenges of starting human clinical trials. It also mentions the need for funding to secure a patent for a protein that promotes hair growth.

The user is considering whether to get a second hair transplant or wait to see the results from switching to oral minoxidil and finasteride. They also use microneedling and ketoconazole shampoo.

A user wants to add tretinoin to their nightly minoxidil and finasteride combo to increase effectiveness. They seek advice on how to mix tretinoin with the existing treatment.

Minoxidil 5% combined with 0.01% tretinoin may be as effective as using minoxidil twice daily. Users discuss switching to oral minoxidil for consistency, with concerns about side effects.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

PP405 is viewed skeptically, with some seeing it as overhyped and potentially ineffective compared to existing treatments like minoxidil and finasteride. While it shows some promise in activating dormant hair follicles, many believe it won't replace hair transplants or significantly outperform current options.

The conclusion of the conversation is that the user has experienced significant hair regrowth using a combination of medications, including dutasteride, RU58841, and minoxidil. They have not experienced any noticeable side effects and are considering a hair transplant in the future.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

Hair cloning technology is advancing, with clinical trials for improved methods expected by 2028 and 2029, potentially offering a solution for hair loss if donor follicles remain. Organtech's expansion into other biotech areas may secure funding, but the effectiveness of cloning depends on the availability of androgen-resistant donor follicles.

The user shared their 5-year hair journey, including a recent hair transplant of 2600 grafts, and their routine of using dutasteride, oral minoxidil, and ketrel. They are hopeful for high-density results and recommend starting treatment early.

A 25-year-old has used minoxidil for 7 years, finasteride for 2 years, oral minoxidil and dutasteride for 3 months, and also tried microneedling and nizoral. They are considering a hair transplant but are concerned about being a good candidate due to potential retrograde alopecia.

Minoxidil, dutasteride, and copper peptides are used in a tattooing method for hair regrowth, with some users noting better results compared to oral treatments. Copper peptides are considered to have minimal impact, but the method may reduce side effects.

The user is using a topical solution with finasteride, minoxidil, and other ingredients, along with a red light laser cap and dermapen, to address hair thinning. They are considering a hair transplant but are advised to try dutasteride and oral minoxidil for 12 to 18 months before deciding.

Rejuv-3X, a topical blend with GHK-Cu, AHK-Cu, and JXL-089, is used for hair loss, offering a targeted option without finasteride's side effects. The user plans to combine it with microneedling for enhanced results.

The user is considering continuing minoxidil and microneedling, possibly adding low-dose topical finasteride, and undergoing a large FUE hair transplant to improve hair appearance. They plan to use hair fibers for added density, aiming for a convincing cosmetic look rather than full density.

The user is pleased with their hair transplant results after nearly 7 months, noting thicker, longer, and stronger hair with good coverage and full donor recovery. They are using oral minoxidil and finasteride.

The conversation discusses the potential use of verteporfin for hair loss treatment, with one user mentioning their surgeon's interest in trying it and another noting its research status and clinical use as a YAP inhibitor. Some users debate the market size, availability of generics, and the optimism in the hair loss community regarding new treatments.

The conversation is about using micro needling and PTD-DBM for hair loss treatment. The user applies PTD-DBM drops on weekdays and performs micro needling weekly.

Switching from finasteride to dutasteride as a treatment for hair loss, and discussing possible side effects or results of the switch.

A trans woman experiencing male pattern baldness has been using Minoxidil and microneedling for 3.5 months, noticing visible hair regrowth. Despite initial skepticism, progress is evident, though a hair transplant might be needed for fuller coverage.

A new topical treatment, TH07, combining finasteride, latanoprost, and minoxidil, is entering phase III trials with promising early results. Some users express skepticism, noting the treatment uses existing products.

The user is considering using Tretinoin every other day alongside daily Minoxidil to manage hair loss and is concerned about inconsistent absorption affecting regrowth. They have noticed a significant reduction in shedding but are unsure if it's due to Tretinoin or the end of the Minoxidil/finasteride shedding phase.

The conversation discusses the use of Verteporfin in treating hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

A 33-year-old male has been using topical dutasteride and minoxidil twice daily, along with a 0.25 mm derma roller every five days, and is experiencing hair shedding but seeing progress. Some users suspect a hair transplant, while others praise the results.

The user is currently using alfatradiol and fluridil for hair loss and is considering adding low-dose topical finasteride but is concerned about potential side effects due to past mental health issues. They are seeking others' experiences with these treatments and their effectiveness.

User shows hair loss progress from NW4 to NW2.5 in 2.5 months using RU 8.5-9% daily and topical Dut .1% + RU 5% weekly. Discussion includes managing tension in African American hair and representation of different hair types.

Combining microneedling with Low Level Laser Therapy (LLLT) for hair growth, with discussions on device legitimacy and effectiveness. Alternatives like PEMF and the use of oral and topical treatments such as dutasteride, minoxidil, and finasteride are also considered.

Topical finasteride may have higher systemic absorption and lower efficacy when using a Propylene Glycol/Ethanol formulation compared to the hydroxypropyl chitosan (HPCH) formulation. The safety profile of topical finasteride relies heavily on the HPCH formulation, and using standard solutions might lead to different pharmacokinetics.

The user is 6 months post-hair transplant and uses finasteride, oral and topical minoxidil, along with supplements like omega-3, vitamin D3, and zinc. They are experiencing significant shedding and seek advice on whether the medications are effective and if the shedding will settle.

A 23-year-old with heart issues is considering a hair transplant but is concerned about using finasteride or minoxidil due to health risks. A suggestion was made to consider topical minoxidil as it may have fewer systemic effects, but ongoing treatment is necessary to maintain transplant results.